CRANBURY, N.J., Aug. 13, 2020 /PRNewswire/ -- Palatin
Technologies, Inc. (NYSE American: PTN), a specialized
biopharmaceutical company developing first-in-class medicines based
on molecules that modulate the activity of the melanocortin and
natriuretic peptide receptor systems, announced that it
participated in Canaccord Genuity's 40th Annual Growth
Conference in a Fireside Chat today at 10:30
am ET. The conference was held virtually.
Carl Spana, Ph.D., President and
Chief Executive Officer and Stephen T.
Wills, Chief Financial Officer and Chief Operating Officer
of Palatin Technologies, participated in the Fireside Chat hosted
by John Newman of Canaccord
Genuity.
The Fireside Chat was webcast. The webcast replay can be
accessed by logging on to the "Investor/Webcasts" section of
Palatin's website at http://www.palatin.com or by clicking the
following link:
https://wsw.com/webcast/canaccord42/ptn/. The webcast will be
available for 90 days.
About Palatin Technologies, Inc.
Palatin
Technologies, Inc. is a specialized biopharmaceutical company
developing first-in-class medicines based on molecules that
modulate the activity of the melanocortin and natriuretic peptide
receptor systems, with targeted, receptor-specific product
candidates for the treatment of diseases with significant unmet
medical need and commercial potential. Palatin's strategy is to
develop products and then form marketing collaborations with
industry leaders in order to maximize their commercial potential.
For additional information regarding Palatin, please visit
Palatin's website at www.Palatin.com.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/palatin-technologies-participates-in-canaccord-genuitys-40th-annual-growth-conference-301112185.html
SOURCE Palatin Technologies, Inc.